Androgen Receptor Antagonists
"Androgen Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and inhibit the activation of ANDROGEN RECEPTORS.
| Descriptor ID |
D059002
|
| MeSH Number(s) |
D06.347.065.249 D27.505.696.399.450.065.249
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Androgen Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Receptor Antagonists".
This graph shows the total number of publications written about "Androgen Receptor Antagonists" by people in this website by year, and whether "Androgen Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 3 | 0 | 3 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 5 | 0 | 5 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgen Receptor Antagonists" by people in Profiles.
-
The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies. Crit Rev Oncol Hematol. 2024 Aug; 200:104420.
-
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer. J Exp Clin Cancer Res. 2023 Jul 29; 42(1):187.
-
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer. 2023 10; 192:113249.
-
Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology. 2023 04 17; 164(6).
-
Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology. 2023 04 17; 164(6).
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
-
The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun. 2022 06 01; 13(1):3057.
-
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 11; 22(11):1541-1559.
-
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. Endocr Relat Cancer. 2021 07 15; 28(8):T19-T38.
-
AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption. Int J Mol Sci. 2021 May 24; 22(11).